NEW YORK (GenomeWeb News) – CytRx subsidiary RXi Pharmaceuticals has licensed short hairpin RNAi technology from Cold Spring Harbor Laboratory, CytRX said today.
Under the licensing agreement, RXi purchased a worldwide, non-exclusive license to the technology, which was developed by Cold Spring Harbor’s Gregory Hannon.
Hannon is a co-founder and member of RXi’s scientific advisory board.
Financial terms of the agreement were not released.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.